A Novel Fully Automated Molecular Diagnostic System (AMDS) for Colorectal Cancer Mutation Detection

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kitano, Shiro ^a   Myers, Jamie ^b   Nakamura, Junko ^a   Yamane, Akio ^a   Yamashita, Mami ^a   Nakayama, Masato ^a   Tsukahara, Yusuke ^c   Ushida, Hiroshi ^a   Liu, Wanqing ^b   Ratain, Mark J ^b   Amano, Masahiko ^a  

^a TOPPAN PRINTING CO LTD   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

^c RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PLASMID DNA;

ALLELE; ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; AUTOMATED MOLECULAR DIAGNOSTIC SYSTEM; BRAF GENE; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DIRECT SEQUENCING; DNA EXTRACTION; GENETIC ALGORITHM; GENOTYPE; HUMAN; HUMAN TISSUE; MUTANT; ONCOGENE; ONCOGENE K RAS; PI3KCA GENE; POINT OF CARE TESTING; SOMATIC MUTATION; WILD TYPE;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FORMALDEHYDE; FROZEN SECTIONS; HUMANS; MUTATION; PARAFFIN EMBEDDING; PATHOLOGY, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION;

EID: 84877314885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062989     Document Type: Article

References (31)

1. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-358.
2. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, et al. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5: 928-932.
3. Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N, (2005) Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16: iv44-49.
4. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
5. Samuels Y, Velculescu VE, (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3: 1221-1224.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
7. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, et al. (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122: 2255-2259.
8. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, et al. (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27: 1477-1484.
9. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820.
10. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
11. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
12. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712.
13. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961.
14. Janne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, et al. (2006) A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12: 751-758.
15. Tatsumi K, Mitani Y, Watanabe J, Takakura H, Hoshi K, et al. (2008) Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn 10: 520-526.
16. Amicarelli G, Shehi E, Makrigiorgos GM, Adlerstein D, (2007) FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res 35: e131.
17. Cross J, (2008) DxS Ltd. Pharmacogenomics 9: 463-467.
18. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, et al. (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7: 413-421.
19. Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, et al. (2010) A comparability study of 5 commercial KRAS tests. Diagn 5: 23.
20. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A, (2008) High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142.
21. Hoshi K, Takakura H, Mitani Y, Tatsumi K, Momiyama N, et al. (2007) Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 13: 4974-4983.
22. Lyamichev V, Mast AL, Hall JG, Prudent JR, Kaiser MW, et al. (1999) Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 17: 292-296.
23. Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B, (1999) Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn 4: 353-364.
24. Kathryn M, Chris S, Robin T, Charles H, (1996) Driving Forces for DNA Adsorption to Silica in Perchlorate Solutions. JOURNAL OF COLLOID AND INTERFACE SCIENCE 181: 635-644.
25. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, et al. (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28: 495-503.
26. Cohen J, (1960) A coefficient of agreement for normal scales. Educational and Psychological Measurement 20: 37-46.
27. Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, et al. (2009) Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 4: e7746.
28. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, et al. (2011) PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6: e22769.
29. Yuan TL, Cantley LC, (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
30. Soulieres D, Greer W, Magliocco AM, Huntsman D, Young S, et al. (2010) KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol 17: S31-40.
31. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.